

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

PerCP/Cyanine5.5 anti-human CD3

RRID:AB_893299

Type: Antibody

Proper Citation

BioLegend Cat# 300430, RRID:AB_893299

Antibody Information

URL: http://antibodyregistry.org/AB_893299

Proper Citation: BioLegend Cat# 300430, RRID:AB_893299

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_893299

Vendor: BioLegend

Catalog Number: 300430

Alternative Catalog Numbers: 300429

Record Creation Time: 20250819T210036+0000

Record Last Update: 20250819T213253+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Li Q, et al. (2025) Macro-scale, scaffold-assisted model of the human bone marrow endosteal niche using hiPSC-vascularized osteoblastic organoids. *Cell stem cell*, 32(12), 1941.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. *Cell reports*, 44(7), 115933.

Das Adhikari U, et al. (2025) Immunometabolic defects of CD8+ T cells disrupt gut barrier integrity in people with HIV. *Cell*.

Zhang QS, et al. (2025) SHMT2 regulates CD8+ T cell senescence via the reactive oxygen species axis in HIV-1 infected patients on antiretroviral therapy. *EBioMedicine*, 112, 105533.

Wu Z, et al. (2025) Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. *Cell*.

Jayasinghe RG, et al. (2025) Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues. *Cell reports*, 44(5), 115587.

Clutton GT, et al. (2024) CD3 downregulation identifies high-avidity human CD8 T cells. *Clinical and experimental immunology*, 215(3), 279.

Thomas P, et al. (2024) High affinity mAb infusion can enhance maximum affinity maturation during HIV Env immunization. *iScience*, 27(4), 109495.

Shin OS, et al. (2024) Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38. *Cell reports*, 43(7), 114502.

Tan J, et al. (2024) STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity. *EBioMedicine*, 101, 105035.

Ruf B, et al. (2023) Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. *Cell*, 186(17), 3686.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN γ production in human natural killer cells. *EMBO reports*, 23(8), e54133.

Rappazzo CG, et al. (2022) Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. *Immunity*, 55(9), 1710.

Poznanski SM, et al. (2021) Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. *Cell metabolism*, 33(6), 1205.

Cardoso A, et al. (2021) Interleukin-10 induces interferon- γ -dependent emergency myelopoiesis. *Cell reports*, 37(4), 109887.

Fels JM, et al. (2021) Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. *Cell*, 184(13), 3486.

Portillo AL, et al. (2021) Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. *iScience*, 24(6), 102619.

Xu S, et al. (2021) Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 $^{+}$ T cells in tumors. *Immunity*, 54(7), 1561.

Leylek R, et al. (2020) Chromatin Landscape Underpinning Human Dendritic Cell Heterogeneity. *Cell reports*, 32(12), 108180.

Ettxeberria I, et al. (2019) Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 $^{+}$ T Cells. *Cancer cell*, 36(6), 613.